Bluejay Diagnostics, Inc. financial data

Symbol
BJDX on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
360 Massachusetts Avenue, Suite 203, Acton, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 440 % +36.4%
Debt-to-equity 24.3 % -35%
Return On Equity -124 % +26.4%
Return On Assets -99.8 % +18.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 554K shares -79.4%
Common Stock, Shares, Outstanding 554K shares -82.1%
Entity Public Float 1.7M USD -43.9%
Common Stock, Value, Issued 55 USD +244%
Weighted Average Number of Shares Outstanding, Basic 183K shares +6591%
Weighted Average Number of Shares Outstanding, Diluted 183K shares +6591%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.47M USD -39.2%
Selling and Marketing Expense 305 USD -99.8%
General and Administrative Expense 3.69M USD -14.5%
Operating Income (Loss) -7.17M USD +30.5%
Nonoperating Income (Expense) -120K USD -378%
Net Income (Loss) Attributable to Parent -7.72M USD +22.5%
Earnings Per Share, Basic -114 USD/shares
Earnings Per Share, Diluted -114 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.3M USD +94.8%
Assets, Current 4.9M USD +52.1%
Property, Plant and Equipment, Net 1.51M USD +17.7%
Operating Lease, Right-of-Use Asset 210K USD -37.1%
Other Assets, Noncurrent 35.3K USD +23%
Assets 6.66M USD +36.7%
Accounts Payable, Current 145K USD -70.5%
Accrued Liabilities, Current 552K USD -50.6%
Liabilities, Current 810K USD -54.3%
Operating Lease, Liability, Noncurrent 109K USD -42.6%
Other Liabilities, Noncurrent 8.57K USD -30.5%
Liabilities 928K USD -53%
Retained Earnings (Accumulated Deficit) -34.7M USD -28.6%
Stockholders' Equity Attributable to Parent 5.73M USD +97.9%
Liabilities and Equity 6.66M USD +36.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.3M USD +21.7%
Net Cash Provided by (Used in) Financing Activities 2.78M USD
Net Cash Provided by (Used in) Investing Activities -35.4K USD +89.6%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 554K shares -82.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.3M USD +94.8%
Deferred Tax Assets, Valuation Allowance 10M USD +30.4%
Deferred Tax Assets, Gross 10M USD +30.4%
Operating Lease, Liability 222K USD -29.8%
Depreciation 19.7K USD -83.6%
Payments to Acquire Property, Plant, and Equipment 35.4K USD -89.6%
Lessee, Operating Lease, Liability, to be Paid 238K USD -31.1%
Property, Plant and Equipment, Gross 1.71M USD -32.5%
Operating Lease, Liability, Current 113K USD -30.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 100K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 113K USD +13.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 16K USD -45.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 25K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 6.36M USD +39.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 25K USD -75%
Operating Lease, Payments 44.2K USD +1.49%
Additional Paid in Capital 28.7M USD +1.48%
Share-based Payment Arrangement, Expense 20.1K USD -89.4%
Interest Expense 186K USD